German Chancellor Friedrich Merz stated that the decision on drug cost reimbursement is an internal matter of the country. He commented this way on the start of a US investigation into pharmaceutical pricing in Germany, Bloomberg reports, writes UNN.
Details
The administration of US President Donald Trump has launched an investigation that could potentially result in the imposition of tariffs. Merz emphasized that he expects Washington to adhere to the future trade agreement between the US and the EU.
As for the reimbursement of costs for modern, innovative medicines by our health insurers, this is a decision that falls within our national jurisdiction
US criticizes healthcare system reform
The dispute was triggered by the reform of the German health insurance system, which involves reducing spending on medicines. US Trade Representative Jamieson Greer accused Germany of "consistently underpaying for innovative pharmaceutical products."
At the same time, Washington stated that the conflict can be resolved through negotiations. The US also continues to insist on revising approaches to drug pricing and increasing their production on American territory.
Merz sees new unity with Trump on Ukraine, calls G7 meeting a "day of hope"17.06.26, 09:25